Press release
Soaring Demand Set to Propel Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market to $3.09 Billion by 2029
Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market
What Is the Expected CAGR for the Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Through 2025?
The market encompassing the chronic inflammatory demyelinating polyneuropathy (cidp) has experienced considerable expansion recently, projected to increase from its valuation of $2.1 billion in 2024 to $2.27 billion by 2025, reflecting an 8.1% compound annual growth rate (CAGR). This upward trend observed historically stems from several factors, including the expanding elderly demographic, enhancements in therapeutic approaches, heightened public and professional recognition leading to earlier disease identification, progress in the understanding of immunology and autoimmune mechanisms, and a growing incidence rate of various autoimmune disorders.
What's the Projected Size of the Global Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market by 2029?
Anticipated for the coming years is a robust expansion within the market for chronic inflammatory demyelinating polyneuropathy (cidp), projected to reach a valuation of $3.09 billion by 2029, reflecting a compound annual growth rate (CAGR) of 7.9%. This upward trajectory throughout the projection timeframe is largely fueled by factors such as the world's progressively older populace, heightened attention directed towards both rare diseases and autoimmune conditions, enhanced availability of medical care, increased patient support and public understanding initiatives, coupled with upgrades in the existing healthcare frameworks. Key developments anticipated during this period encompass a rising incidence of chronic inflammatory demyelinating polyneuropathy, innovations in available therapeutic modalities, escalated research and development efforts, the introduction of biosimilar treatments, and the progression of customized treatment methodologies.
View the full report here:
https://www.thebusinessresearchcompany.com/report/chronic-inflammatory-demyelinating-polyneuropathy-cidp-global-market-report
Top Growth Drivers in the Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Industry: What's Accelerating the Market?
Anticipated growth in spending on healthcare is forecasted to be a key stimulant for the expansion of the market dedicated to chronic inflammatory demyelinating polyneuropathy (CIDP). This upward trend in medical spending is fueled by several elements, including greater capital allocation toward medical facilities, a mounting requirement for sophisticated therapeutic options, broader health insurance ubiquity, and governmental initiatives aiming to broaden access to medical care. Substantial healthcare spending facilitates quicker access to cutting-edge therapies and earlier identification and superior control of CIDP, consequently elevating both the results achieved for patients and their overall wellbeing. To illustrate this point, data released in May 2024 by the Office for National Statistics, a department of the UK government, indicated that overall healthcare expenditure experienced a notable 5.6% rise nominally between 2022 and 2023, representing a substantial quickening when contrasted with the modest 0.9% expansion noted in the preceding year, 2022. Consequently, this escalating expenditure in the healthcare sector is serving as a major impetus behind the market progression for chronic inflammatory demyelinating polyneuropathy (CIDP).
Get your free sample here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=21144&type=smp
What Trends Will Shape the Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Through 2029 and Beyond?
Key players within the chronic inflammatory demyelinating polyneuropathy (CIDP) arena are concentrating their efforts on innovating treatments, particularly intravenous immunoglobulin (IVIG) therapy, with the objectives of boosting therapeutic effectiveness, delivering superior patient results, and achieving more precise and effective immune system regulation for CIDP control. This IVIG treatment modality administers purified antibodies sourced from healthy donors to assist in recalibrating the immune response and mitigating the inflammatory processes characteristic of these autoimmune disorders. Illustratively, Takeda Pharmaceutical Company Limited, a biopharmaceutical entity headquartered in Japan, received clearance from the FDA in January 2024 for GAMMAGARD LIQUID to be utilized as an IVIG option for adult patients diagnosed with CIDP; this authorization permits its deployment as an induction regimen, commencing with a predetermined initial dosage followed by ongoing maintenance administrations to sustain long-term condition handling and elevate neuromuscular capabilities.
What Are the Main Segments in the Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market?
The chronic inflammatory demyelinating polyneuropathy (cidp)market covered in this report is segmented -
1) By Treatment: Intravenous Immunoglobulin; Corticosteroids; Plasmapheresis; Physiotherapy; Other Treatments
2) By Route Of Administration: Intravenous; Oral; Other Routes Of Administration
3) By Diagnosis: Electrodiagnostic Testing; Nerve Conduction; Electromyography (EMG); Spinal Fluid Analysis; Other Diagnosis
4) By Distribution Channel: Hospitals; Pharmacies; Online Pharmacies; Specialty Clinics
5) By End User: Hospitals; Research Institutions; Homecare Settings
Subsegments:
1) By Intravenous Immunoglobulin (IVIG): Standard IVIG Therapy; High-Dose IVIG Therapy
2) By Corticosteroids: Oral Corticosteroids; Intravenous Corticosteroids
3) By Plasmapheresis: Single-Exchange Plasmapheresis; Multiple-Exchange Plasmapheresis
4) By Physiotherapy: Muscle Strengthening Exercises; Balance And Coordination Therapy
5) By Other Treatments: Immunosuppressive Agents; Monoclonal Antibodies
Tailor your insights and customize the full report here:
https://www.thebusinessresearchcompany.com/customise?id=21144&type=smp
Which Top Companies are Driving Growth in the Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market?
Major companies operating in the chronic inflammatory demyelinating polyneuropathy (CIDP) market are Pfizer Inc., Johnson & Johnson, Sanofi SA, Novartis AG, Takeda Pharmaceutical Company Limited, Baxter International Inc., CSL Behring (CSL Limited), Grifols S.A., Sun Pharmaceutical Industries Ltd., Mitsubishi Tanabe Pharma Corporation, Octapharma AG, Cipla Inc., Hikma Pharmaceuticals plc, Halozyme Therapeutics, Hualan Biological Engineering Inc, argenx SE, Hovione, Nihon Pharmaceutical Co. Ltd., Bio Products Laboratory Ltd., AdvaCare Pharma.
Which Regions Will Dominate the Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Through 2029?
North America was the largest region in the chronic inflammatory demyelinating polyneuropathy (CIDP) market in 2024. The regions covered in the chronic inflammatory demyelinating polyneuropathy (CIDP) market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Purchase the full report today:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=21144
This Report Supports:
1.Business Leaders & Investors - To identify growth opportunities, assess risks, and guide strategic decisions.
2.Manufacturers & Suppliers - To understand market trends, customer demand, and competitive positioning.
3.Policy Makers & Regulators - To track industry developments and align regulatory frameworks.
4.Consultants & Analysts - To support market entry, expansion strategies, and client advisory work.
Reach out to us:
The Business Research Company: https://www.thebusinessresearchcompany.com/,
Americas +1 310-496-7795,
Europe +44 7882 955267,
Asia & Others +44 7882 955267 & +91 8897263534,
Email us at info@tbrc.info.
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Learn More About The Business Research Company
With over 17500+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.Our flagship product, the Global Market Model (GMM), is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Soaring Demand Set to Propel Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market to $3.09 Billion by 2029 here
News-ID: 4279237 • Views: …
More Releases from The Business Research Company
Key Players and Competitive Dynamics in the Liver Health Supplements Market
The liver health supplements sector is gaining significant attention as consumers increasingly prioritize holistic wellness and preventive care. With evolving consumer preferences and technological advancements, this market is set to experience robust growth in the coming years. Let's explore the current market size, key drivers, major players, emerging trends, and important segment details shaping this industry.
Forecast of Market Size and Growth Trends in Liver Health Supplements
The liver health…
Market Segmentation, Dynamics, and Competitive Landscape in the Liraglutide Mark …
The liraglutide market is set for significant expansion in the coming years, driven by rising health concerns and evolving treatment preferences worldwide. As demand for effective metabolic disorder therapies grows, this market is poised to deliver substantial growth and innovation through 2030. Let's explore the market size projections, key players, emerging trends, and segmentation details that define the future of liraglutide.
Projected Growth and Size Outlook for the Liraglutide Market Through…
Emerging Sub-Segments Transforming the Levofloxacin Market Landscape
Understanding the future trajectory of the levofloxacin market reveals promising growth driven by evolving healthcare needs and technological advancements. This overview delves into the projected market size, key players, emerging trends, and the segmental breakdown shaping this critical antibiotic sector.
Levofloxacin Market Size Forecast and Expansion to 2030
The levofloxacin market is anticipated to expand significantly through 2030, reaching a valuation of $2.42 billion. This growth corresponds to a compound…
Leading Companies Advancing Innovation and Growth in the Leukemia Therapeutics M …
The leukemia therapeutics market is on the brink of substantial expansion as advancements in treatment strategies and technologies continue to evolve. As researchers and companies focus on more precise and effective therapies, the market is expected to grow significantly by 2030. Here, we explore the anticipated market size, key players, driving forces, and the emerging trends shaping this vital healthcare segment.
Leukemia Therapeutics Market Size and Growth Projections
The leukemia…
More Releases for CIDP
CIDP Therapeutics Market Size, Share and Report 2026-2035
Chronic Inflammatory Demyelinating Polyneuropathy Therapeutics Market Outlook
As per the latest report by Expert Market Research(EMR), The global chronic inflammatory demyelinating polyneuropathy (CIDP) therapeutics market reached a valuation of USD 2.00 Billion in 2025 and is projected to achieve a market value of USD 4.01 Billion by 2035, growing at a CAGR of 7.20%. This expansion is primarily driven by the rising prevalence of autoimmune neuropathies and significant advancements in immunoglobulin…
CIDP Pipeline 2025: FDA Updates, Therapy Innovations, and Clinical Trial Landsca …
(Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, Chronic Inflammatory Demyelinating Polyneuropathy pipeline constitutes 2+ key companies continuously working towards developing 4+ Chronic Inflammatory Demyelinating Polyneuropathy treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.
"Chronic Inflammatory Demyelinating Polyneuropathy Pipeline Insight, 2025" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across…
CIDP Market Emerging Trends and Growth Prospects 2034
Introduction
Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) is a rare, immune-mediated neuropathy characterized by progressive or relapsing weakness, sensory loss, and impaired reflexes due to demyelination of peripheral nerves. Unlike acute Guillain-Barré syndrome, CIDP evolves over at least eight weeks and, without timely treatment, can lead to significant long-term disability. The condition encompasses typical CIDP and several clinical variants (e.g., MADSAM/Lewis-Sumner, DADS, pure motor, pure sensory), each with nuanced diagnostic and therapeutic…
Chronic Inflammatory Demyelinating Polyneuropathy (CIDP): Market Insights and Co …
The Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market sector is undergoing significant transformation, with substantial growth and technological advancements expected by 2031. According to a new in-depth market research report, the sector is poised for expansion, driven by various factors such as market size, share, and emerging trends.
This comprehensive report provides key insights into the Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) market, exploring critical market segmentation and definitions. It highlights the essential…
Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Treatment Market 2024-2 …
Chronic Inflammatory Demyelinating Polyneuropathy Treatment Market is an uncommon autoimmune disorder affecting the peripheral nervous system. It manifests through the progressive weakening of muscles and the loss of sensation in extremities. The CIDP treatment market has shown consistent growth and is poised for significant expansion in the forthcoming years. In this comprehensive blog post, we will delve into the current scenario, regulatory framework, market dynamics, supplier landscape, drug distribution model,…
Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) Market Insights …
The market for chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) was valued USD 968 Million in 2017 which is anticipated to reach USD 2,020.6 Million by 2030.
The total number of CIDP patients in the 7MM is projected to reach 55,113 by 2030 from 46,027 in 2019. The U.S. has the highest incidences of CIDP in the 7MM. In 2019, as per the data studied by Report Ocean, there were approximately 29,000…
